Related Experiment Video
Updated: Jun 16, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Biologic agents-a panacea for inflammatory arthritis or not?
J Ninan1, Malcolm D Smith, M Dugar
1Division of Rheumatology, Repatriation General Hospital, Adelaide 5042, Australia.
International Journal of Rheumatology
|February 5, 2010
Summary
Biological therapy retention for rheumatoid arthritis (RA) patients was lower in a clinical setting compared to psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients. This contrasts with findings from randomized controlled trials (RCTs).
Area of Science:
- Rheumatology
- Immunology
- Clinical Pharmacology
Background:
- Biological therapies are crucial for managing inflammatory autoimmune diseases like rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
- Understanding treatment retention in real-world clinical settings is essential for optimizing patient outcomes.
- Previous studies, often from randomized controlled trials (RCTs), may not fully reflect clinical practice.
Purpose of the Study:
- To evaluate and compare the retention rates of biological therapies across RA, PsA, and AS patient cohorts in a clinical setting.
- To identify potential reasons for treatment discontinuation or switching of biological agents.
- To compare observed retention rates with those reported in existing randomized controlled trials.
Main Methods:
- A retrospective analysis of patients receiving biological therapies at a dedicated clinic in an Australian teaching hospital.
- Assessment of treatment continuation, reasons for switching to alternative biological agents, and reasons for cessation.
- Comparison of retention rates between RA, PsA, and AS patient groups and against published RCT data.
Main Results:
- Rheumatoid arthritis patients exhibited lower retention rates on biological therapies compared to patients with psoriatic arthritis and ankylosing spondylitis.
- The retention rate for RA patients in this clinical setting was significantly lower than reported in randomized controlled trials.
- No clear determinants for nonresponse to biological agents were identified, and these therapies demonstrated limited steroid-sparing effects.
Conclusions:
- Clinical retention of biological therapies for RA is suboptimal compared to other spondyloarthropathies and published RCT data.
- The reasons for lower retention in clinical practice require further investigation, as clear predictors of nonresponse were not identified.
- The limited steroid-sparing capacity of these agents may influence treatment decisions and retention.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...